All In Biotech

Drug Trial Radar · NCT05757466

Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma

Efficacy and Safety Study of Second-Line Prolgolimab Monotherapy or in Combination With Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Dec 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Apr 19, 2023

Primary completion

Mar 10, 2024

Study completion Mar 10, 2025

Sponsor

Lead sponsor
St. Petersburg State Pavlov Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
N.N. Petrov National Medical Research Center of Oncology
First posted
Mar 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prolgolimab is an anti-PD-1 inhibitor that has previously been shown to be effective and safe for the treatment of patients with melanoma. Given the mechanism of action, it is expected to be effective in patients with classical Hodgkin lymphoma (cHL). The use of PD-1 inhibitors in 2nd line treatment, as part of PET-adapted monotherapy/combination therapy, has already demonstrated a favorable toxicity profile, as well as a high efficacy, which may lead to increased survival of patients with r/r cHL. It has been demonstrated that long-term disease remission can be achieved after PD-1 inhibitor therapy, even in a group of heavily pretreated patients with relapsed/refractory cHL. The use of prolgolimab as part of PET-adapted therapy strategy in this study may allow to achieve a prolonged remission in patients with cHL who are highly sensitive to immunotherapy while omitting the autologous stem cell transplantation.

Conditions

  • Hodgkin Lymphoma

Interventions

  • ProlgolimabDrug

    Prolgolimab monotherapy 1 mg/kg IV every 2 weeks up to a maximum of 24 cycles

  • Combination with prolgolimab and bendamustineDrug

    Prolgolimab 1 mg/kg IV D1,15; Bendamustine 90 mg/m2 IV D1,2, 28-day cycle, maximum of 3 cycles;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate during prolgolimab monotherapyTime frame: 12 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • St. Petersburg State Pavlov Medical University

    Saint Petersburg, Russia · Recruiting

  • N.N. Petrov National Medical Research Center of Oncology

    Saint Petersburg, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.